MAVZURE Trademark

Trademark Overview


On Wednesday, April 24, 2019, a trademark application was filed for MAVZURE with the United States Patent and Trademark Office. The USPTO has given the MAVZURE trademark a serial number of 88400708. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 10, 2022. This trademark is owned by Eli Lilly and Company. The MAVZURE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis
mavzure

General Information


Serial Number88400708
Word MarkMAVZURE
Filing DateWednesday, April 24, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 10, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 9, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis
Translation of Words in MarkThe wording "MAVZURE" has no meaning in a foreign language.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 10, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Tuesday, October 11, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 10, 2022ABANDONMENT - NO USE STATEMENT FILED
Saturday, March 5, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 4, 2022SOU EXTENSION 5 GRANTED
Monday, February 21, 2022SOU EXTENSION 5 FILED
Monday, February 21, 2022TEAS EXTENSION RECEIVED
Wednesday, August 18, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 16, 2021SOU EXTENSION 4 GRANTED
Monday, August 16, 2021SOU EXTENSION 4 FILED
Monday, August 16, 2021TEAS EXTENSION RECEIVED
Saturday, February 20, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 18, 2021SOU EXTENSION 3 GRANTED
Thursday, February 18, 2021SOU EXTENSION 3 FILED
Thursday, February 18, 2021TEAS EXTENSION RECEIVED
Thursday, September 10, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 9, 2020SOU EXTENSION 2 GRANTED
Tuesday, August 18, 2020SOU EXTENSION 2 FILED
Monday, August 24, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, August 18, 2020TEAS EXTENSION RECEIVED
Wednesday, February 12, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 10, 2020SOU EXTENSION 1 GRANTED
Monday, February 10, 2020SOU EXTENSION 1 FILED
Monday, February 10, 2020TEAS EXTENSION RECEIVED
Tuesday, September 3, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 9, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 9, 2019PUBLISHED FOR OPPOSITION
Wednesday, June 19, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 28, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, May 20, 2019ASSIGNED TO EXAMINER
Friday, May 10, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, April 27, 2019NEW APPLICATION ENTERED IN TRAM